Japan’s Eisai Says It Still Has Patent Protection For Aricept Despite Court Action (Japan)
This article was originally published in PharmAsia News
Japan's Eisai says a U.S. district court ruling will have no impact on the validity of its patent for Aricept (donepezil hydrochloride) for treating Alzheimer's disease. The court in New Jersey threw out Eisai's suit against Mutual Pharmaceutical for seeking U.S. FDA approval for an Aricept generic. Eisai said the ruling was based on procedural grounds and it is still free to sue Mutual to defend a patent not set to expire until 2010. (Click here for more - may require a subscription
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.